[go: up one dir, main page]

MX2014012978A - Regiones de anticuerpo modificado y sus usos. - Google Patents

Regiones de anticuerpo modificado y sus usos.

Info

Publication number
MX2014012978A
MX2014012978A MX2014012978A MX2014012978A MX2014012978A MX 2014012978 A MX2014012978 A MX 2014012978A MX 2014012978 A MX2014012978 A MX 2014012978A MX 2014012978 A MX2014012978 A MX 2014012978A MX 2014012978 A MX2014012978 A MX 2014012978A
Authority
MX
Mexico
Prior art keywords
modified antibody
antibody regions
regions
modified
antibodies
Prior art date
Application number
MX2014012978A
Other languages
English (en)
Other versions
MX360368B (es
Inventor
Hwai Wen Chang
Jay M Short
Gerhard Frey
Original Assignee
Bioatla Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Llc filed Critical Bioatla Llc
Publication of MX2014012978A publication Critical patent/MX2014012978A/es
Publication of MX360368B publication Critical patent/MX360368B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a regiones de Fc modificadas de anticuerpos, y sus usos, tal como en anticuerpos que contienen una región de Fc de la presente invención.
MX2014012978A 2012-04-27 2013-04-26 Regiones de anticuerpo modificado y sus usos. MX360368B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261639729P 2012-04-27 2012-04-27
PCT/US2013/038538 WO2013163630A1 (en) 2012-04-27 2013-04-26 Modified antibody regions and uses thereof

Publications (2)

Publication Number Publication Date
MX2014012978A true MX2014012978A (es) 2015-02-05
MX360368B MX360368B (es) 2018-10-29

Family

ID=49483948

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014012978A MX360368B (es) 2012-04-27 2013-04-26 Regiones de anticuerpo modificado y sus usos.
MX2018001914A MX382840B (es) 2012-04-27 2013-04-26 Regiones de anticuerpo modificado y sus usos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018001914A MX382840B (es) 2012-04-27 2013-04-26 Regiones de anticuerpo modificado y sus usos.

Country Status (13)

Country Link
US (2) US20150065690A1 (es)
EP (2) EP3470433A1 (es)
JP (1) JP6470170B2 (es)
KR (2) KR20150008082A (es)
CN (1) CN104428317B (es)
AU (3) AU2013251309B2 (es)
BR (1) BR112014026740B1 (es)
CA (1) CA2871807C (es)
HK (1) HK1207654A1 (es)
IN (1) IN2014DN08721A (es)
MX (2) MX360368B (es)
RU (1) RU2014147741A (es)
WO (1) WO2013163630A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2947605A1 (en) 2014-05-13 2015-11-19 Bioatla, Llc Conditionally active biological proteins
FR3038517B1 (fr) * 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
CA3006462C (en) 2015-12-14 2023-10-31 Macrogenics, Inc. Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
SG11201807949WA (en) * 2016-03-14 2018-10-30 Univ Oslo Engineered immunoglobulins with altered fcrn binding
WO2020092155A1 (en) * 2018-10-31 2020-05-07 Bioatla, Llc Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
US20230026259A1 (en) 2019-03-08 2023-01-26 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
WO2020227515A1 (en) 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
WO2021030303A1 (en) 2019-08-12 2021-02-18 Voyager Therapeutics, Inc. High-sensitivity immunoassay for the detection of frataxin in biofluids
WO2021040736A1 (en) 2019-08-30 2021-03-04 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
AR122480A1 (es) * 2020-05-21 2022-09-14 Cadila Healthcare Ltd VARIANTE DE LA Fc Y PREPARACIÓN DE LA MISMA
WO2021234160A2 (en) 2020-05-22 2021-11-25 Formycon Ag Ace2 fusion proteins and uses thereof
CA3193930A1 (en) 2020-10-29 2022-05-05 Formycon Ag Ace2 fusion proteins and uses thereof
AU2022230745A1 (en) 2021-03-03 2023-08-17 Formycon Ag Formulations of ace2 fc fusion proteins
EP4437112A1 (en) 2021-11-24 2024-10-02 Formycon AG Improved ace2 fusion proteins
WO2023094571A1 (en) 2021-11-25 2023-06-01 Formycon Ag Stabilization of ace2 fusion proteins
EP4386084A1 (en) 2022-12-14 2024-06-19 Formycon AG Improved ace2 fusion proteins

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1562972B1 (en) * 2002-10-15 2010-09-08 Facet Biotech Corporation ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004041854A2 (en) 2002-11-05 2004-05-21 Affinium Pharmaceuticals, Inc. Essential novel bacterial polypeptides
US7960512B2 (en) * 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004204494B2 (en) * 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
WO2005037867A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
WO2005047327A2 (en) * 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
CN101189028B (zh) * 2004-07-12 2013-05-29 马克罗基因公司 具有变异Fc区的抗体的鉴定和工程化以及使用方法
EP2471813B1 (en) * 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP2314618A3 (en) 2004-11-12 2011-10-19 Xencor Inc. Fc variants with altered binding to FcRn
US20100104564A1 (en) * 2005-03-29 2010-04-29 Genevieve Hansen Altered Antibody Fc Regions and Uses Thereof
PL1919503T3 (pl) * 2005-08-10 2015-04-30 Macrogenics Inc Identyfikacja i inżynieria przeciwciał ze zmiennymi regionami FC oraz sposoby ich stosowania
AU2006304387A1 (en) * 2005-10-14 2007-04-26 Medimmune, Llc Cell display of antibody libraries
EP2235059B1 (en) * 2007-12-26 2015-02-18 Xencor, Inc. Fc variants with altered binding to fcrn
EP2282770B1 (en) * 2008-06-04 2018-03-07 MacroGenics, Inc. Antibodies with altered binding to fcrn and methods of using same
CN102369291A (zh) 2009-01-23 2012-03-07 比奥根艾迪克Ma公司 效应子功能降低的稳定Fc多肽及使用方法
MX342623B (es) 2009-06-26 2016-10-06 Regeneron Pharma Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original.
TWI667346B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
MX341579B (es) * 2010-08-03 2016-08-25 Abbvie Inc * Inmunoglobulinas de dominio variable doble y usos de las mismas.
US8483058B2 (en) 2010-08-17 2013-07-09 Qualcomm Incorporated Systems and methods for traffic policing
BR112014000524B1 (pt) 2011-07-15 2020-06-23 Basell Poliolefine Italia S.R.L. Cinta de poliolefina compreendendo um copolímero aleatório de propileno com 1-hexeno
CN103975060B (zh) * 2011-09-30 2021-04-13 中外制药株式会社 离子浓度依赖性结合分子文库
WO2013109279A2 (en) * 2012-01-19 2013-07-25 Therapeutic Proteins Inc. Stabilization of the anti-cd20 antibody rituximab

Also Published As

Publication number Publication date
EP2841458A1 (en) 2015-03-04
AU2013251309A1 (en) 2014-10-30
AU2019202229A1 (en) 2019-04-18
BR112014026740A8 (pt) 2021-06-15
BR112014026740B1 (pt) 2022-10-04
MX382840B (es) 2025-03-13
JP6470170B2 (ja) 2019-02-13
IN2014DN08721A (es) 2015-05-22
WO2013163630A1 (en) 2013-10-31
US10954288B2 (en) 2021-03-23
CA2871807A1 (en) 2013-10-31
KR20200037434A (ko) 2020-04-08
HK1207654A1 (en) 2016-02-05
AU2019202229B2 (en) 2021-02-11
EP2841458A4 (en) 2015-09-16
KR20150008082A (ko) 2015-01-21
AU2017225111B2 (en) 2019-01-03
CN104428317A (zh) 2015-03-18
AU2017225111A1 (en) 2017-09-28
AU2013251309B2 (en) 2017-06-22
CN104428317B (zh) 2018-08-28
US20150065690A1 (en) 2015-03-05
BR112014026740A2 (pt) 2017-06-27
MX360368B (es) 2018-10-29
JP2015515497A (ja) 2015-05-28
RU2014147741A (ru) 2016-06-20
US20180186863A1 (en) 2018-07-05
EP3470433A1 (en) 2019-04-17
CA2871807C (en) 2022-10-04

Similar Documents

Publication Publication Date Title
MX360368B (es) Regiones de anticuerpo modificado y sus usos.
NZ739622A (en) Antibodies to tau
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
PH12015502565B1 (en) Anti-transferrin receptor antibodies and methods of use
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
TN2012000366A1 (en) Anticoagulant antidotes
IN2014DN09417A (es)
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
IN2014DN05885A (es)
MX2014014376A (es) Anticuerpos de anti-biotina y metodos de uso.
TN2013000388A1 (en) Anticoagulant antidotes
MX357675B (es) Anticuerpos anti-jagged y métodos de uso.
MX2015010023A (es) Anticuerpos anti-cd83 y su uso.
MX2014014381A (es) Anticuerpos de anti-teofilina y metodos de uso.
NZ743971A (en) Antibodies to tau
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration